American Society of Hirudotherapy

The isomorphous structures of prethrombin2, hirugen-, and PPACK-thrombin: changes accompanying activation and exosite binding to thrombin

Research article published in Protein science : a publication of the Protein Society (1994)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Observational studyDrug DevelopmentSalivary PharmacologyVijayalakshmi et al. · Protein science : a publication of the Protein Society, 1994

Abstract

The X-ray crystal structure of prethrombin2 (pre2), the immediate inactive precursor of alpha-thrombin, has been determined at 2.0 A resolution complexed with hirugen. The structure has been refined to a final R-value of 0.169 using 14,211 observed reflections in the resolution range 8.0-2.0 A. A total of 202 water molecules have also been located in the structure. Comparison with the hirugen-thrombin complex showed that, apart from the flexible beginning and terminal regions of the molecule, there are 4 polypeptide segments in pre2 differing in conformation from the active enzyme (Pro 186-Asp 194, Gly 216-Gly 223, Gly 142-Pro 152, and the Arg 15-Ile 16 cleavage region). The formation of the Ile 16-Asp 194 ion pair and the specificity pocket are characteristic of serine protease activation with the conformation of the catalytic triad being conserved. With the determination of isomorphous structures of hirugen-thrombin and D-Phe-Pro-Arg chloromethyl ketone (PPACK)-thrombin, the changes that occur in the active site that affect the kinetics of chromogenic substrate hydrolysis on binding to the fibrinogen recognition exosite have been determined. The backbone of the Ala 190-Gly 197 segment in the active site has an average RMS difference of 0.55 A between the 2 structures (about 3.7 sigma compared to the bulk structure). This segment has 2 type II beta-bends, the first bend showing the largest shift due to hirugen binding. Another important feature was the 2 different conformations of the side chain of Glu 192. The side chain extends to solvent in hirugen-thrombin, which is compatible with the binding of substrates having an acidic residue in the P3 position (protein-C, thrombin platelet receptor). In PPACK-thrombin, the side chain of Asp 189 and the segment Arg 221A-Gly 223 move to provide space for the inhibitor, whereas in hirugen-thrombin, the Ala 190-Gly 197 movement expands the active site region. Although 8 water molecules are expelled from the active site with PPACK binding, the inhibitor complex is resolvated with 5 other water molecules.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeComparative StudyJournal ArticleResearch Support, U.S. Gov't, P.H.S.
Indexed MeSH termsAmino Acid Chloromethyl KetonesAmino Acid SequenceBinding SitesCrystallography, X-RayEnzyme ActivationEnzyme PrecursorsHirudinsHumansHydrogen BondingModels, MolecularMolecular Sequence DataPeptide FragmentsProtein BindingProtein ConformationProthrombinThrombin

Summary

X-ray structures of prethrombin2 (2.0 A, R-value 0.169), hirugen-thrombin and PPACK-thrombin reveal activation-linked conformational changes in four segments and show how binding of hirugen at the fibrinogen recognition exosite reshapes the thrombin active site.

Why This Matters for Hirudotherapy

This study determined the X-ray crystal structure of prethrombin-2 complexed with hirugen at 2.0 Å resolution and compared it with hirugen-thrombin and PPACK-thrombin complexes to characterize conformational changes accompanying thrombin activation and exosite binding. The findings identify specific polypeptide segments differing between the inactive precursor and the active enzyme, and describe how hirugen binding to the fibrinogen recognition exosite alters active-site geometry, including shifts in the Ala190-Gly197 segment and different conformations of the Glu192 side chain. The study provides atomic-level structural detail on exosite-mediated conformational changes in thrombin. CAVEAT: This is a structural/crystallographic study with no in-vivo context, and the abstract does not specify the origin or nature of hirugen beyond its use as a thrombin-binding molecule; no leech therapy, whole secretome, or clinical application is addressed.

Citation

Reference (Vancouver style)

Vijayalakshmi J, Padmanabhan KP, Mann KG, Tulinsky A. The isomorphous structures of prethrombin2, hirugen-, and PPACK-thrombin: changes accompanying activation and exosite binding to thrombin. Protein Sci. 1994;3(12):2254-2271. doi:10.1002/pro.5560031211. PMID: 7756983

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.